Apolo, A. B., Ballman, K., Sonpavde, G. P., Berg, S., Kim, W., Parikh, R., … Rosenberg, J. E. (2024). 1964MO Alliance A031501: AMBASSADOR study of adjuvant pembrolizumab (Pembro) in muscle-invasive urothelial carcinoma (MIUC) vs observation (Obs): Extended follow-up disease-free survival (DFS) results and metastatic (met) disease recurrence distribution. In Annals of Oncology (Vol. 35, pp. S1135–S1136). Elsevier BV. https://doi.org/10.1016/j.annonc.2024.08.2049

Apolo, A. B., K. Ballman, G. P. Sonpavde, S. Berg, W. Kim, R. Parikh, M. Y. Teo, et al. “1964MO Alliance A031501: AMBASSADOR study of adjuvant pembrolizumab (Pembro) in muscle-invasive urothelial carcinoma (MIUC) vs observation (Obs): Extended follow-up disease-free survival (DFS) results and metastatic (met) disease recurrence distribution.” In Annals of Oncology, 35:S1135–36. Elsevier BV, 2024. https://doi.org/10.1016/j.annonc.2024.08.2049.

Apolo AB, Ballman K, Sonpavde GP, Berg S, Kim W, Parikh R, et al. 1964MO Alliance A031501: AMBASSADOR study of adjuvant pembrolizumab (Pembro) in muscle-invasive urothelial carcinoma (MIUC) vs observation (Obs): Extended follow-up disease-free survival (DFS) results and metastatic (met) disease recurrence distribution. In: Annals of Oncology. Elsevier BV; 2024. p. S1135–6.

Apolo, A. B., et al. “1964MO Alliance A031501: AMBASSADOR study of adjuvant pembrolizumab (Pembro) in muscle-invasive urothelial carcinoma (MIUC) vs observation (Obs): Extended follow-up disease-free survival (DFS) results and metastatic (met) disease recurrence distribution.” Annals of Oncology, vol. 35, Elsevier BV, 2024, pp. S1135–36. Crossref, doi:10.1016/j.annonc.2024.08.2049.

Apolo AB, Ballman K, Sonpavde GP, Berg S, Kim W, Parikh R, Teo MY, Sweis RF, Geynisman D, Grivas P, Chatta G, Reichert Z, Kim JW, Bilen MA, McGregor BA, Srinivas S, Halabi S, Perez Burbano G, Morris MJ, Rosenberg JE. 1964MO Alliance A031501: AMBASSADOR study of adjuvant pembrolizumab (Pembro) in muscle-invasive urothelial carcinoma (MIUC) vs observation (Obs): Extended follow-up disease-free survival (DFS) results and metastatic (met) disease recurrence distribution. Annals of Oncology. Elsevier BV; 2024. p. S1135–S1136.